InflaRx NV IFRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/24/24 EDT
1.44quote price arrow down-0.04 (-2.70%)
Volume
209,563
52 week range
1.14 - 4.70
Loading...
  • Open1.49
  • Day High1.51
  • Day Low1.43
  • Prev Close1.48
  • 52 Week High4.70
  • 52 Week High Date06/21/23
  • 52 Week Low1.14
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap84.792M
  • Shares Out58.88M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.21
  • YTD % Change-11.66

KEY STATS

  • Open1.49
  • Day High1.51
  • Day Low1.43
  • Prev Close1.48
  • 52 Week High4.70
  • 52 Week High Date06/21/23
  • 52 Week Low1.14
  • 52 Week Low Date11/10/23
  • Market Cap84.792M
  • Shares Out58.88M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.21
  • YTD % Change-11.66

RATIOS/PROFITABILITY

  • EPS (TTM)-0.76
  • P/E (TTM)-1.89
  • Fwd P/E (NTM)-1.65
  • EBITDA (TTM)-50.019M
  • ROE (TTM)-47.58%
  • Revenue (TTM)107,189.998
  • Gross Margin (TTM)-659.40%
  • Net Margin (TTM)-41,602.89%
  • Debt To Equity (MRQ)1.21%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On InflaRx NV

 

Profile

MORE
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial...
Nicolas Fulpius
Independent Chairman of the Board
Niels Riedemann M.D., Ph.D.
Chief Executive Officer, Executive Director
Thomas Taapken
Chief Financial Officer
Address
Winzerlaer Str. 2
Jena
07745
Germany

Top Peers

SYMBOLLASTCHG%CHG
ATHA
Athira Pharma Inc
2.64+0.08+3.12%
GNLX
Genelux Corp
2.62-1.98-43.04%
ANVS
Annovis Bio Inc
7.29+0.21+2.97%
MIST
Milestone Pharmaceuticals Inc
1.71-0.04-2.29%
LPTX
Leap Therapeutics Inc
2.38-0.09-3.64%